{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:54:27Z","timestamp":1764510867408,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T02:13:42Z","timestamp":1713492822000},"page":"611-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1270-3825","authenticated-orcid":false,"given":"Matthew R.","family":"LeBlanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-203X","authenticated-orcid":false,"given":"Christopher D.","family":"Baggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-1573","authenticated-orcid":false,"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6673-335X","authenticated-orcid":false,"given":"Christopher E.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eben I.","family":"Lichtman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel M.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2024.04.005_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2024.04.005_bib0002","unstructured":"U.S. Food and Drug Administration. Hematology\/oncology (cancer) approvals & safety notifications. 2023; Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications. Accessed: March 15, 2023."},{"issue":"3","key":"10.1016\/j.clml.2024.04.005_bib0003","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.clml.2024.04.005_bib0004","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.04.005_bib0005","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.04.005_bib0006","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.04.005_bib0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","article-title":"Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study","volume":"10","author":"Hou","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.04.005_bib0008","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San-Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.04.005_bib0009","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.3109\/10428194.2016.1170828","article-title":"Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity","volume":"57","author":"Costa","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2024.04.005_bib0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.04.005_bib0011","doi-asserted-by":"crossref","first-page":"e17586","DOI":"10.1200\/jco.2013.31.15_suppl.e17586","article-title":"Adult participation in oncology clinical trials by indication, race, and age","volume":"31","author":"Combest","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10068","key":"10.1016\/j.clml.2024.04.005_bib0012","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clml.2024.04.005_bib0013","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9757","key":"10.1016\/j.clml.2024.04.005_bib0014","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.clml.2024.04.005_bib0015","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","article-title":"Next-generation multiple myeloma treatment: a pharmacoeconomic perspective","volume":"128","author":"Rajkumar","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2024.04.005_bib0016","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2019.4492","article-title":"Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare part D, 2010 to 2019","volume":"321","author":"Dusetzina","year":"2019","journal-title":"JAMA"},{"year":"2021","series-title":"SEER Cancer Statistics Review, 1975-2018","author":"Howlader","key":"10.1016\/j.clml.2024.04.005_bib0017"},{"issue":"55","key":"10.1016\/j.clml.2024.04.005_bib0018","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.clml.2024.04.005_bib0019","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index\u2014CPI for all urban consumers. Data Tools 2023; Available at: https:\/\/data.bls.gov\/cgi-bin\/dsrv?cu. Accessed: March 13, 2023."},{"issue":"3","key":"10.1016\/j.clml.2024.04.005_bib0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.clml.2024.04.005_bib0021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12913-023-09189-x","article-title":"The effectiveness of clinical guideline implementation strategies in oncology: a systematic review","volume":"23","author":"Bora","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"10.1016\/j.clml.2024.04.005_bib0022","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J R Soc Med"},{"issue":"2","key":"10.1016\/j.clml.2024.04.005_bib0023","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.04.005_bib0024","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.clml.2024.04.005_bib0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.04.005_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clml.2024.04.005_bib0027","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1158\/1078-0432.CCR-20-0841","article-title":"Efficacy and tolerability of high- versus low-dose lenalidomide maintenance therapy of multiple myeloma after autologous blood stem cell transplantation","volume":"26","author":"Fenk","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:27:36Z","timestamp":1724473656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502400154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S215226502400154X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}